Immunotherapeutic strategies for invasive bladder cancer: a comprehensive review

Immunotherapeutic strategies for invasive bladder cancer: a comprehensive review

Bladder cancer is a prevalent malignancy, with muscle-invasive bladder cancer (MIBC) presenting a significant therapeutic challenge. Standard treatments, including radical cystectomy (RC) and neoadjuvant chemotherapy, pose substantial risks and impact quality of life, leading to increasing interest...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yingying Wang, Min He, Jian Li, Li Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-04-01
Series:	Frontiers in Immunology
Subjects:	bladder cancer immunotherapy PD-1/PD-L1 inhibitors bladder-preserving therapy neoadjuvant immunotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1591379/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Advances in the immunological microenvironment and immunotherapy of bladder cancer
by: Le Meng, et al.
Published: (2025-08-01)

MODERN POSSIBILITIES OF THERAPY WITH INHIBITORS OF CONTROL POINTS IN METASTATIC UROTHELIAL CANCER
by: R. A. Gafanov, et al.
Published: (2018-03-01)

Toripalimab treatment of bladder-preserving therapy for locally advanced bladder cancer: a case report
by: Zhiyun Yang, et al.
Published: (2025-06-01)

Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors
by: Wenke Li, et al.
Published: (2025-07-01)

Mapping the immunological landscape and emerging immunotherapeutic strategies in cervical cancer: a comprehensive review
by: Xinyi Zhang, et al.
Published: (2025-07-01)

Enhancing cancer care with improved checkpoint inhibitors
by: Vickram A S, et al.
Published: (2024-10-01)

Advances in PD-1/PD-L1 pathway inhibitors in the treatment of thyroid cancer: mechanisms and clinical therapeutic perspectives
by: Xizi Li, et al.
Published: (2025-08-01)

Advancements in bladder cancer immunotherapy: a focus on intravesical approaches
by: Xia Tang, et al.
Published: (2025-07-01)

Immunotherapy as an Innovative Treatment for Non-Small Cell Lung Cancer – A Comprehensive Literature Review
by: Aneta Rasińska, et al.
Published: (2025-05-01)

Clinical characteristics, outcomes, and predictive modeling of patients diagnosed with immune checkpoint inhibitor therapy-related pneumonitis
by: Antonious Hazim, et al.
Published: (2025-05-01)

Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer
by: Hongshu Li, et al.
Published: (2025-04-01)

Deciphering riddles in molecular subtyping of bladder cancer
by: Yuxiao Li, et al.
Published: (2025-04-01)

B and T lymphocyte attenuator (BTLA) and PD-1 pathway dual blockade promotes antitumor immune responses by reversing CD8+ T-cell exhaustion in non-small cell lung cancer
by: Yang Zhang, et al.
Published: (2025-05-01)

Combined radiation and immune checkpoint inhibitor therapy for metastatic or recurrent hepatocellular carcinoma: a real-world study of 108 patients
by: Yirui Zhai, et al.
Published: (2025-08-01)

The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer
by: Vesna Ćeriman Krstić, et al.
Published: (2025-01-01)

Modern possibilities of using immunotherapy in the treatment of cervical cancer
by: A. V. Tarasova, et al.
Published: (2021-09-01)

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
by: Yizhou Zhang, et al.
Published: (2024-12-01)

Optimizing Immunotherapy: The Synergy of Immune Checkpoint Inhibitors with Artificial Intelligence in Melanoma Treatment
by: Mohammad Saleem, et al.
Published: (2025-04-01)

Novel neoadjuvant therapies for muscle‐invasive bladder cancer: Systematic review and meta‐analysis
by: Shugo Yajima, et al.
Published: (2025-05-01)

Structural and temporal dynamics analysis of PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: History, research hotspots, and emerging trends
by: Talaiti Tuergan, et al.
Published: (2025-12-01)

LAG3, TIM3 and TIGIT: New Targets for Immunotherapy and Potential Associations with Radiotherapy
by: Camil Ciprian Mireștean, et al.
Published: (2025-04-01)

TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives
by: Zhuohong Yan, et al.
Published: (2025-05-01)

Characterisation of the tumour microenvironment and PD-L1 granularity reveals the prognostic value of cancer-associated myofibroblasts in non-invasive bladder cancer
by: Carmen G. Cañizo, et al.
Published: (2025-12-01)

Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer
by: Dalia Elsayed, et al.
Published: (2023-04-01)

Comprehensive characterization of PD-L1 expression and immunotherapy-related genomic biomarkers in early- versus advanced-stage non-small cell lung cancer
by: Yujie Chen, et al.
Published: (2025-05-01)

Current Status and Future Perspectives of Immunotherapies in Bladder Cancer
by: Gökhan Çolak, et al.
Published: (2025-08-01)

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison
by: Wei Chen, et al.
Published: (2025-01-01)

Synergies between radiotherapy and immunotherapy: a systematic review from mechanism to clinical application
by: JingLong Jiang, et al.
Published: (2025-08-01)

Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies
by: Annapaola Montagner, et al.
Published: (2024-12-01)

Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic
by: Maite Alvarez, et al.
Published: (2023-12-01)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
by: Miao Wang, et al.
Published: (2021-12-01)

Engineered PD-L1 co-expression in PD-1 knockout and MAGE-C2-targeting TCR-T cells augments the cytotoxic efficacy toward target cancer cells
by: Fangxin Zhao, et al.
Published: (2025-04-01)

The current status and prospects of gut microbiota combined with PD-1/PD-L1 inhibitors in the treatment of colorectal cancer: a review
by: Min Deng, et al.
Published: (2025-05-01)

Metabolism of tryptophan in non-small lung cancer patients with different effect of PD-1 / PD-L1 inhibitors immunotherapy
by: E. Yu. Zlatnik, et al.
Published: (2022-06-01)

The potential role of HPV oncoproteins in the PD-L1/PD-1 pathway in cervical cancer: new perspectives on cervical cancer immunotherapy
by: Jin Li, et al.
Published: (2024-12-01)

Efficacy and Safety of PD-1/PD-L1 Inhibitors in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
by: Zhen-Yu Li, et al.
Published: (2023-09-01)

Comparison of treatment outcome between first‐line combination immunotherapy (anti‐PD‐L1 or anti‐PD1) with or without chemotherapy and chemotherapy alone in advanced non‐small cell lung cancer patients in tertiary care hospital
by: Danainut Naratornsirakul, et al.
Published: (2024-07-01)

A phase II study of neoadjuvant chemotherapy followed by organ preservation in patients with muscle-invasive bladder cancer
by: Chinna Babu Dracham, et al.
Published: (2022-07-01)

Research advances in immune agonists and their nanoparticles for enhancing the immunotherapeutic efficacy of PD-1 inhibitors in malignancies
by: Renjie Xia, et al.
Published: (2025-08-01)

Temporal Effect on PD‐L1 Detection and Novel Insights Into Its Clinical Implications in Non–Small Cell Lung Cancer
by: Gopal P. Pathak, et al.
Published: (2024-10-01)